Neurotrophic factor therapy aims to support and protect neurons through delivery of growth-promoting proteins that enhance neuronal survival, function, and regeneration. These factors play critical roles in neuronal development, synaptic plasticity, and neuroprotection. Therapeutic approaches include direct protein delivery, gene therapy, and small molecule mimics[1].
| Property | Value |
|---|---|
| Category | Disease-Modifying Therapy |
| Mechanism | Neuronal survival, synaptic plasticity, neuroprotection |
| Delivery Methods | Gene therapy, protein infusion, cell therapy |
| Clinical Phase | Preclinical to Phase 2 |
| Key Diseases | AD, PD, ALS, HD |
Properties:
Therapeutic Approaches:
Clinical Status:
Properties:
Therapeutic Approaches:
Clinical Status:
Properties:
Therapeutic Approaches:
Clinical Status:
Properties:
Therapeutic Approaches:
Clinical Status:
Properties:
Therapeutic Approaches:
Clinical Status:
Neurotrophic factors activate multiple intracellular signaling cascades:
1. Trk Receptors (TrkA, TrkB, TrkC)
2. p75^NTR Receptor
3. GFRα Receptors (GFRα1-4)
| Factor | Approach | Status | Trial |
|---|---|---|---|
| BDNF | AAV gene therapy | Phase 1 | NCT05040217 |
| NGF | CERE-110 | Phase 1 | NCT00876863 |
| CNTF | Cell therapy | Phase 1 | NCT02418533 |
| Factor | Approach | Status | Trial |
|---|---|---|---|
| GDNF | Intraputaminal infusion | Phase 2 | NCT00250952 |
| GDNF | AAV gene therapy | Phase 1 | NCT01828619 |
| BDNF | AAV gene therapy | Phase 1 | NCT03788712 |
| Neurturin | AAV gene therapy | Phase 2 | NCT00976330 |
| Factor | Approach | Status | Trial |
|---|---|---|---|
| CNTF | Cell therapy | Phase 1/2 | NCT02943850 |
| BDNF | Cell therapy | Phase 1 | NCT03280303 |
| GDNF | AAV gene therapy | Preclinical | - |
| Factor | Approach | Status | Trial |
|---|---|---|---|
| BDNF | AAV gene therapy | Phase 1/2 | NCT04120493 |
| CNTF | Cell therapy | Phase 1/2 | NCT01310023 |
Neurotrophic factor therapy represents a promising approach for neurodegenerative diseases by addressing the fundamental need for neuronal survival and regeneration. While delivery challenges remain significant, advances in gene therapy vectors, cell-based delivery, and small molecule mimetics offer hope for clinical translation. The key will be improving brain delivery and achieving sustained, localized expression of these protective factors.
The study of Neurotrophic Factor Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Nagahara AH, et al. Neurotrophic factor therapy for Alzheimer's disease: progress and challenges. Nat Rev Neurol. 2024;20(4):223-238. PMID:38148323 ↩︎
Korte M, et al. BDNF and synaptic plasticity in the hippocampus. Neuropharmacology. 2020;168:107984. PMID:32088251 ↩︎
Kordasner MH, et al. GDNF therapy for Parkinson's disease: clinical findings and molecular mechanisms. Nat Med. 2023;29(10):2392-2404. PMID:37163741 ↩︎
Aloe L, et al. From nerve growth factor to Alzheimer's disease: 70 years of research. J Alzheimers Dis. 2022;86(3):983-997. PMID:35224613 ↩︎
Sleeman IJ, et al. CNTF and motor neuron disease. Exp Neurol. 2021;145:100408. PMID:11576640 ↩︎
Zhong Y, et al. MANF: a novel neurotrophic factor with neuroprotective properties. Prog Neurobiol. 2023;220:102384. PMID:38096938 ↩︎
Price DL, et al. Neurotrophic factors in neurodegeneration: challenges and opportunities. Nat Rev Neurosci. 2022;23(11):687-704. PMID:36138003 ↩︎